Dry Eye Syndrome – China Drug Forecast and Market Analysis to 2024

Pages: 192 Published: November 01, 2015 Report Code: GDHC298CFR

  • Overview
  • Contents
  • Tables
  • Figures
  • Listen

DES, also known as keratoconjunctivitis sicca, is a multifactorial disease of the tears and ocular surface. This ocular condition can cause ocular discomfort, visual disturbances, and tear film instability, which can potentially damage the ocular surface. The DES market has had few new therapeutics in the last decade with Japan seeing the most change in this time with the arrival of Diquas and Mucosta in 2010 and 2013, respectively. However, the lack of treatment options is about to change with the expected launch of numerous pipeline DES drugs during the forecast period, which will be a significant driver of growth in the 9MM. Indeed, this change has already been initiated with Ikervis’ recent arrival in Europe in 2015. Furthermore, additional marketing approvals are being sought for currently marketed DES drugs, Restasis and Diquas, in new countries in the 9MM, which will provide a source of growth in this market. The value of the Chinese DES market is expected to rise over the forecast period at a CAGR of 10.4%. In 2018, the size of the DES market in China is anticipated to exceed that of the Indian market, and will become the third largest single market from that point forward. GlobalData expects Santen’s Hialid, a sodium hyaluronate-based artificial tears product, to retain its position as the top-selling DES eye prescription drug in China over the forecast period, generating drug sales of $138.5m in 2024. *This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.


Overview of DES including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

Detailed information on the key drugs in China including product description, safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for the top drugs in China from 2014-2024.

Analysis of the impact of key events as well the drivers and restraints affecting China DES market.

Reasons to Buy

Understand and capitalize by identifying products that are most likely to ensure a robust return

Stay ahead of the competition by understanding the changing competitive landscape for DES.

Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

Make more informed business decisions from insightful and in-depth analysis of drug performance

Obtain sales forecast for drugs from 2014-2024 in China.

Table of Contents

1Table of Contents

1.1List of Tables

1.2List of Figures


2.1Related Reports

3Disease Overview

3.1Etiology and Pathophysiology



3.2Disease Classification



3.5Quality of Life

4Disease Management

4.1Diagnosis and Treatment Overview


4.1.2Treatment Guidelines

4.1.3Clinical Practice


5Competitive Assessment


5.2Product Profiles

5.2.1Restasis (cyclosporine)

5.2.2Diquas (diquafosol tetrasodium)

5.2.3Mucosta ophthalmic solution (rebamipide)

5.2.4Ikervis (cyclosporine)

5.2.5Artificial Tears

5.2.6Other therapies

6Unmet Need and Opportunity


6.2New Therapies for DES

6.2.1Unmet Need

6.2.2Gap Analysis


6.3Better Diagnostic Tools

6.3.1Unmet Need

6.3.2Gap Analysis


6.4Appropriate Clinical Trial Design to Secure Regulatory Approval

6.4.1Unmet Need

6.4.2Gap Analysis


6.5Simplified Dosing

6.5.1Unmet Need

6.5.2Gap Analysis


6.6Patient Education to Improve Tolerance and Compliance

6.6.1Unmet Need

6.6.2Gap Analysis


6.7Improved Physician and Patient Disease Awareness

6.7.1Unmet Need

6.7.2Gap Analysis


7Pipeline Assessment


7.2Clinical Trial Mapping

7.2.1Clinical Trial Design for DES

7.2.2Ora for DES Drug Development

7.3Promising Drugs in Clinical Development







7.4Promising Drugs in Early-Stage Development




7.4.4Dextenza (OTX-DP)

7.5Other Drugs in Development

8Market Outlook



8.1.2Key Events

8.1.3Drivers and Barriers





9.4Forecasting Methodology

9.4.1Diagnosed DES Patients

9.4.2Percent Drug-Treated Patients

9.4.3Launch Dates

9.4.4General Pricing Assumptions

9.4.5Individual Drug Assumptions

9.4.6Pricing of Pipeline Agents

9.5Primary Research – KOLs Interviewed for this Report

9.6Primary Research – High-prescriber Survey

9.7About the Authors


9.7.2Therapy Area Director


9.7.4Global Head of Healthcare

9.8About GlobalData


List of Tables

Table 1: Symptoms of Dry Eye Syndrome

Table 2: National and International Treatment Guidelines for DES

Table 3: Country Profile – China

Table 4: Leading Treatments for DES, 2015

Table 5: Product Profile – Restasis

Table 6: Restasis SWOT Analysis, 2015

Table 7: Global Sales Forecast ($m) for Restasis, 2014–2024

Table 8: Product Profile – Diquas

Table 9: Diquas SWOT Analysis, 2015

Table 10: Global Sales Forecast ($m) for Diquas, 2014–2024

Table 11: Product Profile – Mucosta

Table 12: Mucosta SWOT Analysis, 2015

Table 13: Global Sales Forecast ($m) for Mucosta, 2014–2024

Table 14: Product Profile – Ikervis

Table 15: Ikervis SWOT Analysis, 2015

Table 16: Global Sales Forecast ($m) for Ikervis, 2014–2024

Table 17: Artificial Tears SWOT Analysis, 2015

Table 18: Global Sales Forecast ($m) for Artificial Tears, 2014-2024

Table 19: Unmet Needs and Opportunities in DES

Table 20: Promising Drugs in Clinical Development for Dry Eye Syndrome, 2015

Table 21: Comparison of Drugs in Development for Dry Eye Syndrome, 2015

Table 22: Product Profile – Lifitegrast

Table 23: SWOT Analysis – Lifitegrast, 2015

Table 24: Global Sales Forecast ($m) for Lifitegrast, 2014–2024

Table 25: Product Profile – Tavilermide

Table 26: SWOT Analysis – tavilermide, 2015

Table 27: Global Sales Forecast ($m) for tavilermide, 2014–2024

Table 28: Product Profile – Visomitin

Table 29: SWOT Analysis – Visomitin, 2015

Table 30: Global Sales Forecast ($m) for Visomitin, 2014–2024

Table 31: Product Profile – RGN-259

Table 32: SWOT Analysis – RGN-259, 2015

Table 33: Global Sales Forecast ($m) for RGN-259, 2014–2024

Table 34: Product Profile – Cis-UCA

Table 35: Product Profile – SI-614

Table 36: Drugs in Development, 2015

Table 37: China Sales Forecast ($m) for DES Therapies, 2014–2024

Table 38: Key Events Impacting Sales for DES in China, 2014–2024

Table 39: DES Market – Drivers and Barriers in China, 2014–2024

Table 40: Key Launch Dates

Table 41: Surveyed High-prescribing Physicians, by Country

List of Figures

Figure 1: Dry Eye Syndrome – Disease Etiology

Figure 2: The Tear Film in normal and dry eye

Figure 3: Varied Symptoms of Dry Eye Syndrome

Figure 4: Dry Eye Syndrome Therapeutics – Phase II and II/III Clinical Trials in the 9MM, 2015

Figure 5: DES Phase II/Phase III Pipeline, 2015

Figure 6: Competitive Assessment of Late-Stage Pipeline Agents in DES, 2014–2024

Figure 7: Clinical and Commercial Positioning of lifitegrast

Figure 8: Clinical and Commercial Positioning of tavilermide

Figure 9: Clinical and Commercial Positioning of Visomitin

Figure 10: Clinical and Commercial Positioning of RGN-259

Figure 11: Drug Sales for DES Therapies in China, 2014 and 2024


Can be used by individual purchaser only


Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.